NCT03594227 - ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

June 6, 2019

Study Completion Date

June 18, 2019

Conditions

Alopecia

Interventions

DRUG

ATI-501 400mg BID (Low dose)

ATI-501 400mg BID oral low dose for oral administration

DRUG

ATI-501 600mg BID (Mid dose)

ATI-501 600mg BID oral mid dose for oral administration

DRUG

ATI-501 800mg BID (High dose)

ATI-501 800mg BID high dose for oral administration

DRUG

Placebo

Placebo - oral administration

Trial Locations (25)

10075

Aclaris Investigator Site, New York

14623

Aclaris Investigator Site, Rochester

23502

Aclaris Investigator Site, Norfolk

24501

Aclaris Investigator Site, Lynchburg

29607

Aclaris Investigator Site, Greenville

30078

Aclaris Investigator Site, Snellville

32771

Aclaris Investigator Site, Sanford

33137

Aclaris Investigator Site, Miami

33472

Aclaris Investigator Site, Boynton Beach

37215

Aclaris Investigator Site, Nashville

37922

Aclaris Investigator Site, Knoxville

48038

Aclaris Investigator Site, Clinton Township

48202

Aclaris Investigator Site, Detroit

55432

Aclaris Investigator Site, Fridley

55455

Aclaris Investigator Site, Minneapolis

64506

Aclaris Investigator Site, Saint Joseph

68144

Aclaris Investigator Site, Omaha

71913

Aclaris Investigator Site, Hot Springs

72758

Aclaris Investigator Site, Rogers

77056

Aclaris Investigator Site, Houston

78213

Aclaris Investigator Site, San Antonio

78745

Aclaris Investigational Site, Austin

80210

Aclaris Investigator Site, Denver

89148

Aclaris Investigator Site, Las Vegas

97223

Aclaris Investigator Site, Portland